Xiamen Amoytop Biotech Co., Ltd.

This phase 3 study tests a new weekly growth hormone injection (inpegsomatropin) against an existing one (givopegsomatropin) in 84 girls with Turner syndrome who have short stature. The goal is to see which works better for increasing growth over 52 weeks. Participants are prepub…

This Phase 2a trial tests a new long-acting growth hormone injection called inpegsomatropin in 36 adults with growth hormone deficiency. Participants receive different doses or a placebo once a week to check safety and how well the drug works. The goal is to see if this weekly sh…

This study tests a new once-weekly growth hormone injection (inpegsomatropin) against the standard daily growth hormone shot in 141 children born small for gestational age who remain short. The goal is to see if the weekly shot works as well or better at helping kids grow taller …

This study tests a new growth hormone medicine (inpegsomatropin) given once a week compared to the standard daily growth hormone shot. About 300 children with idiopathic short stature (short for no known medical reason) will receive either the weekly or daily injection for one ye…

This phase 2 trial tests two doses of peginterferon alfa-2b in 27 adults with essential thrombocythemia, a blood disorder causing too many platelets, who did not respond to or could not tolerate standard therapy. Participants receive weekly injections for up to 96 weeks. The stud…